Business Wire

KnowBe4's Annual Phishing Benchmarking Report Reveals UK & Ireland Outperform Global Average in Cybersecurity Awareness

Share

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today released its new 2024 Phishing by Industry Benchmarking Report to measure an organization’s Phish-prone™ Percentage (PPP), which indicates how many of their employees are likely to fall for phishing or social engineering scams.

This year’s report shows that according to baseline testing done and conducted across industries, in general, British and Irish employees fare better at 32.3% than the worldwide average of 34.3%. This means that, more often than not, employees in the United Kingdom and Ireland (UK&I) are more vigilant in identifying malicious links and other forms of phishing.

KnowBe4 analysed 54 million simulated phishing tests involving nearly 12 million users across 55,675 organisations in 19 different industries, establishing a PPP baseline that reflects the click rates on phishing tests by employees without KnowBe4 security training.

The findings in the report clearly demonstrate the effectiveness of combining simulated phishing security tests with security awareness training. British and Irish organizations that engaged in consistent training and testing experienced a substantial decrease in their average PPP to 18.4% within the first 90 days, and a further reduction to 4.5% after a year of continuous training and testing. This is a significant improvement from the previous year’s results and underscores the value of regular, targeted training.

These results are below the global average of 18.9% after 90 days and 4.6% after one year of consistent training and testing, suggesting that employees in these regions are well informed and more familiar with the tactics of cybercriminals. Despite being a front-runner when compared to the rest of Europe, organisations must continue to focus on mitigating the human risk that exists when safeguarding against cyber threats.

The considerable overall improvement in PPP over three and 12 months is evidence that transforming cybersecurity culture requires breaking existing habits to make way for more secure ones. As employees adopt new behaviours and these become habitual, they evolve into standard practices that shape organisational culture, creating a workforce that instinctively prioritises security.

Some interesting facts highlighted and discussed in the report include:

  • The UK&I region has seen an increase in attacks on organisations of all sizes, particularly on critical national infrastructure, as well as attacks on individuals with access to high-risk information
  • Ransomware continues to be one of the most dominant cyber threats with phishing as its most common attack vector
  • The increased risk of disruptive misinformation and disinformation campaigns due to local elections
  • The severe economic impact of cyber attacks
  • 71% of organisations report that cybersecurity is a high priority for their senior management, but due to tough economic conditions it often falls to the wayside
  • AI is lowering the barrier of entry to novice cybercriminals allowing them to carry out effective attacks

"AI-driven threats are bound to increase, targeting individuals through social engineering and spreading disinformation," says Javvad Malik, lead security awareness advocate at KnowBe4. "It’s imperative that organisations continue to mitigate human risk alongside technological defences to effectively counter cyber threats. It’s thus encouraging to see a growing trend of organisations in the UK and Ireland starting to move beyond awareness to actively focus on employee behavioural change and establishing strong security cultures."

This year’s report also examines phishing benchmarks from North America, South America, Europe, Africa, Asia, Australia and New Zealand.

To download a copy of the 2024 KnowBe4 Phishing by Industry Benchmarking Report, click here.

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 65,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. The late Kevin Mitnick, who was an internationally recognized cybersecurity specialist and KnowBe4’s Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Organizations rely on KnowBe4 to mobilize their end users as their last line of defense and trust the KnowBe4 platform to strengthen their security culture and reduce human risk.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information please contact:
Kathy Wattman at pr@knowbe4.com
727-474-9950

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure22.6.2024 00:00:00 EEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 23:58:00 EEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 23:30:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 23:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye